Status: Recruiting
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
This study aims to compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus immunotherapy maintenance in the treatment of locally advanced unresectable esophageal squamous cell carcinoma, and to exploratorily identify molecular biomarkers associated with treatment efficacy and toxicity.
Participants needed: 98
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Ning Jiang, M.D./Ph.D.Updated: Apr 15, 2026Locations: 1
Eligibility criteria
The patient or their legal representative is able to sign the written informed c... [+14]
History of other malignancies; [+16]